Clinical trials are crucial for advancing cancer care, but the information about them can be dense and difficult for patients to grasp. This often leads to low enrollment and participation, hindering the progress of potentially life-saving research. Could artificial intelligence offer a solution? A new study explored the use of large language models (LLMs), like the technology behind ChatGPT, to transform complex clinical trial informed consent forms into easy-to-understand summaries and multiple-choice quizzes. Researchers used GPT-4 to generate plain-language summaries of key trial elements, including purpose, procedures, risks, and benefits. They then tested these summaries with patients undergoing informed consent for another study. The results were encouraging: Patients found the AI-generated summaries easy to understand and felt they provided enough information to decide whether to learn more. Importantly, most patients reported that the summaries improved their overall understanding of the clinical trial process. The researchers also investigated the ability of LLMs to create multiple-choice questions to assess patient comprehension of trial details. These AI-generated quizzes showed high accuracy and agreement with expert-written questions, suggesting LLMs could automate the creation of tools to gauge patient understanding. While the results are promising, the study also revealed the need for human oversight. The AI occasionally generated inaccuracies or “hallucinations,” emphasizing the importance of clinicians reviewing and editing the AI-generated materials before they reach patients. This research highlights the potential of AI to make clinical trial information more accessible and understandable to patients, potentially boosting enrollment and improving informed consent. Though still in its early stages, this work suggests AI could play a vital role in streamlining and enhancing the clinical trial process, ultimately benefiting both patients and researchers.